Hainan Shuangcheng Pharmaceuticals Co., Ltd.

SZSE:002693 Stock Report

Market Cap: CN¥10.2b

Hainan Shuangcheng Pharmaceuticals Valuation

Is 002693 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002693 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 002693's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 002693's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002693?

Key metric: As 002693 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 002693. This is calculated by dividing 002693's market cap by their current book value.
What is 002693's PB Ratio?
PB Ratio22.9x
BookCN¥433.88m
Market CapCN¥10.16b

Price to Book Ratio vs Peers

How does 002693's PB Ratio compare to its peers?

The above table shows the PB ratio for 002693 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.5x
603567 Heilongjiang ZBD Pharmaceutical
1.4xn/aCN¥10.9b
300199 Hybio Pharmaceutical
14.8xn/aCN¥10.2b
300026 Tianjin Chase Sun PharmaceuticalLtd
1.4x34.4%CN¥12.0b
002755 Beijing Aosaikang Pharmaceutical
4.3x21.7%CN¥12.5b
002693 Hainan Shuangcheng Pharmaceuticals
22.9xn/aCN¥10.2b

Price-To-Book vs Peers: 002693 is expensive based on its Price-To-Book Ratio (22.9x) compared to the peer average (5.5x).

Price to Book Ratio vs Industry

How does 002693's PB Ratio compare vs other companies in the CN Pharmaceuticals Industry?

1 CompanyPrice / BookEstimated GrowthMarket Cap
002435 Changjiang Runfa Health Industry
0.1xn/aUS$63.75m
No more companies available in this PB range
002693 22.9xIndustry Avg. 2.2xNo. of Companies36PB01.22.43.64.86+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 002693 is expensive based on its Price-To-Book Ratio (22.9x) compared to the CN Pharmaceuticals industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is 002693's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002693 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio22.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 002693's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

7D

3.7%

1Y

7.9%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

7D

-1.8%

1Y

12.8%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

7D

-3.1%

1Y

-24.5%